Fatty acid metabolism in pulmonary arterial hypertension: Role in right ventricular dysfunction and hypertrophy

Pulmonary Circulation

Volumn 5, Issue 2, 2015, Pages 269-278

  Talati, Megha ^a   Hemnes, Anna ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Fatty acid oxidation; Fatty acid transporter (CD36); Glucose oxidation; Glucose transporters; Insulin resistance; Lipotoxic cardiomyopathy; Metabolic syndrome; Pulmonary arterial hypertension; Right ventricle; Right ventricular lipotoxicity

Indexed keywords

EID: 85026339672     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.1086/681227     Document Type: Review

References (113)

1. Tonelli AR, Zein J, Ioannidis JP. Geometry of the randomized evidence for treatments of pulmonary hypertension. Cardiovasc Ther 2013;31:e138-e146.
2. Dittrich HC, Nicod PH, Chow LC, Chappuis FP, Moser KM, Peterson KL. Early changes of right heart geometry after pulmonary thromboendarterectomy. J Am Coll Cardiol 1988;11:937-943.
3. Chow LC, Dittrich HC, Hoit BD, Moser KM, Nicod PH. Doppler assessment of changes in right-sided cardiac hemodynamics after pulmonary thromboendarterectomy. Am J Cardiol 1988;61:1092-1097.
4. Katz WE, Gasior TA, Quinlan JJ, et al. Immediate effects of lung transplantation on right ventricular morphology and function in patients with variable degrees of pulmonary hypertension. J Am Coll Cardiol 1996;27:384-391.
5. Pasque MK, Trulock EP, Cooper JD, et al. Single lung transplantation for pulmonary hypertension: single institution experience in 34 patients. Circulation 1995;92:2252-2258.
6. Toyooka S, Kusano KF, Goto K, et al. Right but not left ventricular function recovers early after living-donor lobar lung transplantation in patients with pulmonary arterial hypertension. J Thorac Cardiovasc Surg 2009;138:222-226.
7. Kramer MR, Valantine HA, Marshall SE, Starnes VA, Theodore J. Recovery of the right ventricle after single-lung transplantation in pulmonary hypertension. Am J Cardiol 1994;73:494-500.
8. Ritchie M, Waggoner AD, Davila-Roman VG, Barzilai B, Trulock EP, Eisenberg PR. Echocardiographic characterization of the improvement in right ventricular function in patients with severe pulmonary hypertension after single-lung transplantation. J Am Coll Cardiol 1993;22:1170-1174.
9. Schulman LL, Leibowitz DW, Anandarangam T, et al. Variability of right ventricular functional recovery after lung transplantation. Transplantation 1996;62:622-625.
10. Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 1997;34: 25-33
11. Gomez-Arroyo J, Mizuno S, Szczepanek K, et al. Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial hypertension. Circ Heart Fail 2013;6:136-144
12. Voelkel NF, Gomez-Arroyo J, Abbate A, Bogaard HJ, Nicolls MR. Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J 2012;40:1555-1565
13. Hemnes AR, Brittain EL, Trammell AW, et al. Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 2014;189:325-334
14. Piao L, Fang YH, Parikh K, Ryan JJ, Toth PT, Archer SL. Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension. J Mol Med 2013;91:1185-1197
15. Quaife RA, Chen MY, Lynch D, et al. Importance of right ventricular end-systolic regional wall stress in idiopathic pulmonary arterial hypertension: a new method for estimation of right ventricular wall stress. Eur J Med Res 2006;11:214-220
16. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115:343-349
17. Sandoval J, Bauerle O, Palomar A, et al. Survival in primary pulmonary hypertension: validation of a prognostic equation. Circulation 1994;89:1733-1744
18. Voelkel NF, Quaife RA, Leinwand LA, et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006;114:1883-1891
19. Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 2009;135:794-804
20. Vonk-Noordegraaf A, Souza R. Cardiac magnetic resonance imaging: what can it add to our knowledge of the right ventricle in pulmonary arterial hypertension? Am J Cardiol 2012;110(suppl):25S-31S
21. Kuehne T, Yilmaz S, Steendijk P, et al. Magnetic resonance imaging analysis of right ventricular pressure-volume loops: in vivo validation and clinical application in patients with pulmonary hypertension. Circulation 2004;110:2010-2016
22. van de Veerdonk MC, Kind T, Marcus JT, et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 2011;58:2511-2519
23. Fukui S, Ogo T, Morita Y, et al. Right ventricular reverse remodelling after balloon pulmonary angioplasty. Eur Respir J 2014;43:1394-1402
24. Drake JI, Bogaard HJ, Mizuno S, et al. Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. Am J Respir Cell Mol Biol 2011;45:1239-1247
25. Zaffran S, Kelly RG, Meilhac SM, Buckingham ME, Brown NA. Right ventricular myocardium derives from the anterior heart field. Circ Res 2004;95:261-268
26. Kusachi S, Nishiyama O, Yasuhara K, Saito D, Haraoka S, Nagashima H. Right and left ventricular oxygen metabolism in openchest dogs. Am J Physiol 1982;243:H761-H766
27. Bing RJ, Siegel A, Vitale A, et al. Metabolic studies on the human heart in vivo. I. Studies on carbohydrate metabolism of the human heart. Am J Med 1953;15:284-296
28. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions: potential for pharmacological interventions. Cardiovasc Res 1997;33:243-257
29. Randle PJ, Priestman DA, Mistry SC, Halsall A. Glucose fatty acid interactions and the regulation of glucose disposal. J Cell Biochem 1994;55(suppl):1-11
30. van der Vusse GJ, van Bilsen M, Glatz JF. Cardiac fatty acid uptake and transport in health and disease. Cardiovasc Res 2000;45:279-293
31. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120: 1640-1645
32. Heresi GA, Aytekin M, Newman J, DiDonato J, Dweik RA. Plasma levels of high-density lipoprotein cholesterol and outcomes in pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;182: 661-668
33. Zamanian RT, Hansmann G, Snook S, et al. Insulin resistance in pulmonary arterial hypertension. Eur Respir J 2009;33:318-324
34. Pugh ME, Robbins IM, Rice TW, West J, Newman JH, Hemnes AR. Unrecognized glucose intolerance is common in pulmonary arterial hypertension. J Heart Lung Transplant 2011;30:904-911
35. Burger CD, Foreman AJ, Miller DP, Safford RE, McGoon MD, Badesch DB. Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the Registry to Evaluate Early and Long-Term PAH Disease Management with normative values from the National Health and Nutrition Examination Survey. Mayo Clin Proc 2011;86:105-112
36. Aijaz B, Ammar KA, Lopez-Jimenez F, Redfield MM, Jacobsen SJ, Rodeheffer RJ. Abnormal cardiac structure and function in the meta- bolic syndrome: a population-based study. Mayo Clin Proc 2008;83: 1350-1357
37. Ahn MS, Kim JY, Youn YJ, et al. Cardiovascular parameters correlated with metabolic syndrome in a rural community cohort of Korea: the ARIRANG study. J Korean Med Sci 2010;25:1045-1052
38. Turhan H, Yasar AS, Yagmur J, Kurtoglu E, Yetkin E. The impact of metabolic syndrome on left ventricular function: evaluated by using the index of myocardial performance. Int J Cardiol 2009;132:382-386
39. Mancia G, Bombelli M, Corrao G, et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007;49:40-47
40. Tadic M, Ivanovic B, Kostic N, Simic D, Matic D, Celic V. Metabolic syndrome and left ventricular function: is the number of criteria actually important? Med Sci Monit 2012;18:CR282-CR289
41. Azevedo A, Bettencourt P, Almeida PB, et al. Increasing number of components of the metabolic syndrome and cardiac structural and functional abnormalities—cross-sectional study of the general population. BMC Cardiovasc Disord 2007;7:17
42. de las Fuentes L, Brown AL, Mathews SJ, et al. Metabolic syndrome is associated with abnormal left ventricular diastolic function independent of left ventricular mass. Eur Heart J 2007;28:553-559
43. Patel DA, Srinivasan SR, Chen W, Berenson GS. Influence of the metabolic syndrome versus the sum of its individual components on left ventricular geometry in young adults (from the Bogalusa Heart Study). Am J Cardiol 2009;104:69-73
44. Mahmud A, Almuntaser I, Brown A, King G, Crean P, Feely J. Left ventricular structural and functional changes in the metabolic syndrome. J Cardiometab Syndr 2009;4:81-88
45. Huang P, Kraja AT, Tang W, et al. Factor relationships of metabolic syndrome and echocardiographic phenotypes in the HyperGEN study. J Hypertens 2008;26:1360-1366
46. Rurik I, Sandholzer H, Kalabay L. Does the dynamicity of weight gain predict elements of metabolic syndrome? differences in weight gain of hypertensive, diabetic, and obese elderly patients: a pilot study in primary care. Med Sci Monit 2009;15:CR40-CR44
47. Tadic M, Ivanovic B, Grozdic I. Metabolic syndrome impacts the right ventricle: true or false? Echocardiography 2011;28:530-538
48. Karakurt O, Oztekin S, Yazihan N, Akdemir R. Impaired right ventricular functions in metabolic syndrome patients with preserved left ventricular ejection fraction. Turk Kardiyol Dern Ars 2011;39:549-556
49. Zamanian RT, Hemnes A, Praestgaard A, Tracy R, Lima JA, Bluemke DA, Barr RG, Kawut SM. Insulin resistance and right ventricular structure and function: the MESA-Right Ventricle Study. Am J Respir Crit Care Med 185:2012:A3453
50. Benson L, Brittain EL, Pugh ME, et al. Impact of diabetes on survival and right ventricular compensation in pulmonary arterial hypertension. Pulm Circ 2014;4:311-318
51. Belly MJ, Tiede H, Morty RE, et al. HbA1c in pulmonary arterial hypertension: a marker of prognostic relevance? J Heart Lung Transplant 2012;31:1109-1114
52. West J, Niswender KD, Johnson JA, et al. A potential role for insulin resistance in experimental pulmonary hypertension. Eur Respir J 2013; 41:861-871
53. Kluge R, Barthel H, Pankau H, et al. Different mechanisms for changes in glucose uptake of the right and left ventricular myocardium in pulmonary hypertension. J Nucl Med 2005;46:25-31
54. Bokhari S, Raina A, Rosenweig EB, et al. PET imaging may provide a novel biomarker and understanding of right ventricular dysfunction in patients with idiopathic pulmonary arterial hypertension. Circ Cardiovasc Imaging 2011;4:641-647
55. Lundgrin EL, Park MM, Sharp J, et al. Fasting 2-deoxy-2-[18F]fluoro- D-glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year. Ann Am Thorac Soc 2013;10:1-9
56. Takeyama D, Kagaya Y, Yamane Y, et al. Effects of chronic right ventricular pressure overload on myocardial glucose and free fatty acid metabolism in the conscious rat. Cardiovasc Res 1995;29:763-767
57. Fang YH, Piao L, Hong Z, et al. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle’s cycle. J Mol Med 2012;90:31-43
58. Nagaya N, Goto Y, Satoh T, et al. Impaired regional fatty acid uptake and systolic dysfunction in hypertrophied right ventricle. J Nucl Med 1998;39:1676-1680
59. Kim Y, Goto H, Kobayashi K, et al. Detection of impaired fatty acid metabolism in right ventricular hypertrophy: assessment by I-123 β-methyl iodophenyl pentadecanoic acid (BMIPP) myocardial singlephoton emission computed tomography. Ann Nucl Med 1997;11:207-212
60. O’Connor RD, Xu J, Ewald GA, et al. Intramyocardial triglyceride quantification by magnetic resonance spectroscopy: in vivo and ex vivo correlation in human subjects. Magn Reson Med 2011;65:1234-1238
61. Ng AC, Delgado V, Bertini M, et al. Myocardial steatosis and biventricular strain and strain rate imaging in patients with type 2 diabetes mellitus. Circulation 2010;122:2538-2544
62. Szczepaniak LS, Dobbins RL, Metzger GJ, et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med 2003;49: 417-423
63. Chiu HC, Kovacs A, Ford DA, et al. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 2001;107:813-822
64. Habets DD, Coumans WA, Voshol PJ, et al. AMPK-mediated increase in myocardial long-chain fatty acid uptake critically depends on sarcolemmal CD36. Biochem Biophys Res Commun 2007;355:204-210
65. Tanaka T, Nakata T, Oka T, et al. Defect in human myocardial longchain fatty acid uptake is caused by FAT/CD36 mutations. J Lipid Res 2001;42:751-759
66. Luiken JJ, Koonen DP, Willems J, et al. Insulin stimulates long-chain fatty acid utilization by rat cardiac myocytes through cellular redistribution of FAT/CD36. Diabetes 2002;51:3113-3119
67. van Oort MM, van Doorn JM, Bonen A, et al. Insulin-induced translocation of CD36 to the plasma membrane is reversible and shows similarity to that of GLUT4. Biochim Biophys Acta 2008;1781:61-71
68. Coort SL, Luiken JJ, van der Vusse GJ, Bonen A, Glatz JF. Increased FAT (fatty acid translocase)/CD36-mediated long-chain fatty acid uptake in cardiac myocytes from obese Zucker rats. Biochem Soc Trans 2004;32:83-85
69. Ouwens DM, Diamant M, Fodor M, et al. Cardiac contractile dysfunction in insulin-resistant rats fed a high-fat diet is associated with elevated CD36-mediated fatty acid uptake and esterification. Diabetologia 2007;50:1938-1948
70. Lally JS, Jain SS, Han XX, et al. Caffeine-stimulated fatty acid oxidation is blunted in CD36 null mice. Acta Physiol 2012;205:71-81
71. Glatz JF, Angin Y, Steinbusch LK, Schwenk RW, Luiken JJ. CD36 as a target to prevent cardiac lipotoxicity and insulin resistance. Prostaglandins Leukot Essent Fatty Acids 2013;88:71-77
72. Talati M, Penner N, Funke M, et al. BMPR2 mutation and Western diet are associated with altered lipid transport and lipotoxicity in the right ventricle. AJRCCM Conference. Am J Respir Crit Care Med 2014;189:A2338
73. Jucker BM, Doe CP, Schnackenberg CG, et al. PPARδ activation normalizes cardiac substrate metabolism and reduces right ventricular hypertrophy in congestive heart failure. J Cardiovasc Pharmacol 2007;50:25-34
74. Sung MM, Koonen DP, Soltys CL, Jacobs RL, Febbraio M, Dyck JR. Increased CD36 expression in middle-aged mice contributes to obesityrelated cardiac hypertrophy in the absence of cardiac dysfunction. J Mol Med 2011;89:459-469
75. Garcia-Rua V, Otero MF, Lear PV, et al. Increased expression of fatty-acid and calcium metabolism genes in failing human heart. PloS ONE 2012;7:e37505
76. Strom CC, Aplin M, Ploug T, et al. Expression profiling reveals differences in metabolic gene expression between exercise-induced cardiac effects and maladaptive cardiac hypertrophy. FEBS J 2005;272:2684-2695
77. Korvald C, Elvenes OP, Myrmel T. Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Physiol Heart Circ Physiol 2000;278:H1345-H1351
78. Abozguia K, Clarke K, Lee L, Frenneaux M. Modification of myocardial substrate use as a therapy for heart failure. Nat Clin Practice Cardiovasc Med 2006;3:490-498
79. Piao L, Fang YH, Cadete VJ, et al. The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. J Mol Med 2010;88:47-60
80. Oikawa M, Kagaya Y, Otani H, et al. Increased [18F]fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol. J Am Coll Cardiol 2005;45:1849-1855
81. Simonsen S, Kjekshus JK. The effect of free fatty acids on myocardial oxygen consumption during atrial pacing and catecholamine infusion in man. Circulation 1978;58:484-491
82. Fessel JP, Hamid R, Wittmann BM, et al. Metabolomic analysis of bone morphogenetic protein receptor type 2 mutations in human pulmonary endothelium reveals widespread metabolic reprogramming. Pulm Circ 2012;2:201-213
83. Ussher JR, Lopaschuk GD. The malonyl CoA axis as a potential target for treating ischaemic heart disease. Cardiovasc Res 2008;79:259-268
84. Dyck JR, Hopkins TA, Bonnet S, et al. Absence of malonyl coenzyme A decarboxylase in mice increases cardiac glucose oxidation and protects the heart from ischemic injury. Circulation 2006;114:1721-1728
85. Dyck JR, Cheng JF, Stanley WC, et al. Malonyl coenzyme A decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Circ Res 2004;94: e78-e84
86. Gilde AJ, van Bilsen M. Peroxisome proliferator-activated receptors (PPARS): regulators of gene expression in heart and skeletal muscle. Acta Physiol Scand 2003;178:425-434
87. Cheng L, Ding G, Qin Q, et al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-δ deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 2004;10:1245-1250
88. Planavila A, Rodriguez-Calvo R, Jove M, et al. Peroxisome proliferator-activated receptor β/δ activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res 2005;65:832-841
89. Marsboom G, Wietholt C, Haney CR, et al. Lung 18F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;185:670-679
90. Xu W, Koeck T, Lara AR, et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci USA 2007;104: 1342-1347
91. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006;3:177-185
92. Dang CV, Hamaker M, Sun P, Le A, Gao P. Therapeutic targeting of cancer cell metabolism. J Mol Med 2011;89:205-212
93. Marsboom G, Toth PT, Ryan JJ, et al. Dynamin-related protein 1- mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension. Circ Res 2012;110:1484-1497
94. Piao L, Sidhu VK, Fang YH, et al. FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate. J Mol Med 2013;91:333-346
95. Metallo CM, Gameiro PA, Bell EL, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2012;481: 380-384
96. Holloway GP, Jain SS, Bezaire V, et al. FAT/CD36-null mice reveal that mitochondrial FAT/CD36 is required to upregulate mitochondrial fatty acid oxidation in contracting muscle. Am J Physiol Regul Integr Comp Physiol 2009;297:R960-R967
97. Yang J, Sambandam N, Han X, et al. CD36 deficiency rescues lipotoxic cardiomyopathy. Circ Res 2007;100:1208-1217
98. Ouwens DM, Boer C, Fodor M, et al. Cardiac dysfunction induced by high-fat diet is associated with altered myocardial insulin signalling in rats. Diabetologia 2005;48:1229-1237
99. Noureddine L, Azzam R, Nemer G, et al. Modulation of total ceramide and constituent ceramide species in the acutely and chronically hypoxic mouse heart at different ages. Prostaglandins Other Lipid Mediat 2008;86:49-55
100. Glenn DJ, Wang F, Nishimoto M, et al. A murine model of isolated cardiac steatosis leads to cardiomyopathy. Hypertension 2011;57:216-222.
101. Parra V, Moraga F, Kuzmicic J, et al. Calcium and mitochondrial metabolism in ceramide-induced cardiomyocyte death. Biochim Biophys Acta 2013;1832:1334-1344
102. Duncan JG, Bharadwaj KG, Fong JL, et al. Rescue of cardiomyopathy in peroxisome proliferator-activated receptor-α transgenic mice by deletion of lipoprotein lipase identifies sources of cardiac lipids and peroxisome proliferator-activated receptor-α activators. Circulation 2010;121:426-435
103. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fattyacid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1:785-789
104. Neves FA, Cortez E, Bernardo AF, et al. Heart energy metabolism impairment in Western-diet induced obese mice. J Nutr Biochem 2014; 25:50-57
105. van den Brom CE, Bosmans JW, Vlasblom R, et al. Diabetic cardiomyopathy in Zucker diabetic fatty rats: the forgotten right ventricle. Cardiovasc Diabetol 2010;9:25
106. Chavez JA, Knotts TA, Wang LP, et al. A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J Biol Chem 2003;278:10297-10303
107. Park TS, Hu Y, Noh HL, et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 2008;49:2101-2112
108. An D, Kewalramani G, Chan JK, et al. Metformin influences cardiomyocyte cell death by pathways that are dependent and independent of caspase-3. Diabetologia 2006;49:2174-2184
109. Johnson JA, West J, Maynard KB, Hemnes AR. ACE2 improves right ventricular function in a pressure overload model. PloS ONE 2011;6: e20828
110. Takeda M, Yamamoto K, Takemura Y, et al. Loss of ACE2 exaggerates high-calorie diet-induced insulin resistance by reduction of GLUT4 in mice. Diabetes 2013;62:223-233
111. Miatello R, Vazquez M, Renna N, Cruzado M, Zumino AP, Risler N. Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am J Hypertens 2005;18:864-870
112. Steinbusch LK, Luiken JJ, Vlasblom R, et al. Absence of fatty acid transporter CD36 protects against Western-type diet-related cardiac dysfunction following pressure overload in mice. Am J Physiol Endocrinol Metab 2011;301:E618-E627
113. Harrington LS, Moreno L, Reed A, et al. The PPARβ/δ agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension. PloS ONE 2010;5:e9526.